

**Author Guidelines**

Mission

*Contact Lens Spectrum* is an authoritative, evidence-based, peer-to-peer source for current clinical developments in cornea, tear film, and contact lenses. These guidelines are also applicable to all e-newsletters and supplements that are editorial content of *Contact Lens Spectrum*.

Submission Details

* GENERAL STYLE and CONTENT INSTRUCTIONS
* Submissions should generally be original and not been previously published (other than as an abstract) or concurrently submitted elsewhere.
* *Contact Lens Spectrum* uses plagiarism detection software to screen for unoriginal material. Authors should be aware that their paper may be submitted to plagiarism detection software at any point during the peer-review or production process. Where overlap is found, the results of the check will be examined by *CLS* to establish whether it constitutes plagiarism or if there are legitimate reasons for the overlap. If the former is determined, author(s) will be asked to rework/rewrite the piece or sections to ensure a delivery of original content.
* Artificial intelligence (AI)-based software (of non-human origin) cannot be credited with authorship. It also cannot be used to develop editorial content (prose) without advanced special approval of the CLS editorial staff. Prose generated by AI submitted without CLS pre-approval will not be considered, even with attribution of the originating source(s).
* Please limit your authors to 5 or less (if more than that is required, please seek approval from the managing editor). Each author is expected to have contributed intellectually to the submission and has given approval to the submitting author to be named as a co-author.
* *Contact Lens Spectrum* publishes articles of varying lengths, so a specific word count is not necessary. A typical feature article may be approximately 2-3,000 words (3-4 journal pages) and contain between 2 and 5 figures, pictures, or tables. *Contact Lens Spectrum* does not print patient testimonials.
* *Contact Lens Spectrum* does not print information within its editorial pages on branded or generic products or organizations (or product logos, styles, trademarks), with few exceptions.
* Columns and articles should discuss product categories rather than individual products.
* Exceptions may include within a case report (if directly relevant to a full understanding of the case), within the context of original research (e.g., a clinical trial directly comparing therapeutics or medical devices), when a new product launches (within ~6 months of product launch, *Contact Lens Spectrum* may allow one editorial mention of the new product), or within the Product or Industry Focus columns.
* Include a title page with the authors listed, their primary affiliations, contact information (email, telephone, fax), and highest academic degrees (we do not print other honorific or society-based recognitions). Please also list acknowledgements on this page, if any.
* Prescriptions and refractive errors should be in minus cylinder format as follows: OD: -1.00 -2.00 X 090.
* Submit all artwork with the manuscript electronically in TIFF, JPEG, or .png format with a resolution > 300 dpi. We can use only some electronic artwork that is embedded in Microsoft Word, PowerPoint, or Excel.
* *Contact Lens Spectrum* also try to balance the use of personal pronouns, not using them to excess.
* CASE REPORTS/CASE SERIES
* Case reports and series are infrequently printed and must be of exceptional uniqueness and value.
* Please contact the editorial staff prior to submitting a case report or series.
* RESEARCH SUBMISSIONS
* Original research submissions should follow a “Methods, Results, and Discussion” format.
* If the submission qualifies as a research submission (DHHS/FDA 45 CFR 46.102(d), <http://www.hhs.gov/ohrp/humansubjects/guidance/invitrodev.html>), the authors must confirm that the research followed the tenets of the Declaration of Helsinki, that the protocol was approved by an Institutional/Ethics Review Board, and that subjects provided informed consent and stated in the “Methods” section of the submission.
* If the research qualifies as being “exempt” by an IRB/ethics board (i.e., a records review), this must also be stated in the “Methods” section of the submission.
* All original clinical trials (intervention-based studies) must have been registered on clinicaltrials.gov prior to enrollment of the first subject.
* BIOSKETECHES
* Include author(s) headshot and brief narrative biosketch that includes your highest academic degree(s), primary affiliation, one qualifying credential (e.g., a Fellowship or advanced certification), and your financial disclosures.
* FINANCIAL DISCLOSURES
* A current financial disclosure form for each author must be submitted prior to review of the submission.
* Any sources full or partial funding or support of the manuscript or research must be disclosed in an “Acknowledgement” section.
* Disclosure information will be printed in the article in the author’s biographical sketch.
* REFERENCES
* References should be cited when concepts are quoted or paraphrased from another source, facts or opinions are presented that are found in another work, or when non-original ideas used are in the formulation of concepts.
* If verbiage refers to “studies” those studies must be cited at the end of the paragraph.
* Advertisements, advertorials, news stories, and “data on file” are not acceptable references.
* Avoid using derivations of original work (e.g., reviews)—cite the original research.
* Ensure your references are accurate and verified.
* Do not preferentially cite your own or peers, institutions, or country references.
* Do not use excessive number of citations to support a singular point.
* Supply a list of references before the column or feature article will be reviewed in the order in which they appear in the article and in the following format:
  + Holden BA, Mertz GW. Critical oxygen levels to avoid corneal edema for daily and extended wear contact lenses. *Invest Ophthalmol Vis Sci*. 1984 Oct;25:1161-1167.
* For columns, use an (Author, Year) format in the article text, which contributes to the overall word count.
* For feature articles, use superscript numbers in the article text.
* For feature articles, please limit the total number of references in the article to 35 or less (additional references can be provided outside of the article text and will be printed online).

Submission Review Process

* Your manuscript may be reviewed by any member of our editorial staff for its appropriateness and content; we may also ask independent experts to review your submission. Unfortunately, we cannot accept all manuscripts that we receive.
* Authors may request that their research article undergo “Peer-Review” whereby 1-2 independent reviewers will be asked to assess the manuscript. If accepted for publication, articles undergoing peer-review will be highlighted in the journal as such.
* *Contact Lens Spectrum* will edit accepted submissions for clarity, length, and style. Please be advised that our style is to use active voice when possible rather than passive voice and we will edit manuscripts to match this style when applicable.
* Once accepted for publication, authors will have the opportunity to see the final edited submission before it goes to press. Editors will e-mail the edited submission to the primary author for approval during production. Response within 24-48 hours is sometimes necessary.
* Once accepted, authors must complete the “Author Agreement” form assigning copyright of the submission.

**Contact Lens Spectrum Editorial Staff**

**Editor-in-Chief**

Jason J. Nichols, OD MPH PhD

The University of Alabama at Birmingham

(205)975-3497

Jason.nichols@pentavisionmedia.com

**Clinical Features Editor**

Edward S. Bennett, OD MSEd

University of Missouri College of Optometry

(314)516-6258

ebennett@umsl.edu

**Editorial Director**

Erinn Morgan

*Contact Lens Spectrum, Eyecare Business,* PentaVision director of social media

(917)561-8685

Erinn.morgan@pentavisionmedia.com

**Managing Editor**

Kerri Ann Raimo

*Contact Lens Spectrum, Eyecare Business*

(215)767-6182

Kerri.raimo@pentavisionmedia.com

**Senior/Social Media Editor**

Deborah Fisher

*Contact Lens Spectrum*

Deborah.fisher@pentavisionmedia.com

**Custom Projects Director**

Susan Tarrant

*Contact Lens Spectrum*

(267)564-6809

Susan.tarrant@pentavisionmedia.com

**Publisher**

Mark Durrick

(215)485-3334

Mark.durrick@pentavisionmedia.com

**Thank you for your submission to *Contact Lens Spectrum*. Please review the information provided in this packet to ensure quick review of your materials. Your submission must be in compliance with all information needed before it will be reviewed for publication.**

***Contact Lens Spectrum* AUTHOR CHECKLIST:**

**Confirm that submission complies with *Contact Lens Spectrum* Author Guidelines (attached).**

**Confirm that a head-shot and short bio (<25 words) are included with the submission for ALL authors.**

**Confirm that the financial disclosure form (page 2) is included with the submission for ALL authors. Please return this form to the editorial office. Note that your manuscript will not be reviewed by our editorial staff until these materials are completed and that this information will be included in your biosketch in the final version if the manuscript is accepted for publication.**

**Confirm that you have included a Bibliography at the end of your manuscript. Note that we do not allow “data on file” references—all references must be publicly accessible. For feature articles, please limit the total number of references to 30 or less.**

**If the manuscript is accepted for publication, you agree to sign and return the “Author Agreement” forms as discussed in the Author Guidelines.**

**ORIGINAL RESEARCH SUBMISSIONS**

**\*Includes patient-based surveys, retrospective chart reviews, & clinical trials.**

**If this is a research submission (including survey and retrospective chart review research), ensure that IRB approval and Human Subjects protections are addressed in the Methods, and registration on clinicaltrials.gov occurred before the first study subject was enrolled (for intervention-based clinical trials).**

**If this is a research submission (including survey and retrospective chart review research), please let editorial staff know if you desire “Peer-Review” of your research. Articles that undergo a “Peer-Review” (as opposed to Editor or Editorial Board Review) will be designated as such upon acceptance and when published in the journal.**

### FINANCIAL DISCLOSURE FORM

***Please respond to the following statement:***

**I, or a member of my immediate family, or my corporation, or my employer *acting on my behalf* (e.g., my university), currently have or within the preceding 12 months had a financial relationship with a Designated Company.**

"Designated Company" for these purposes means a legal entity (or subsidiary or division) engaged in the manufacture or distribution of contact lenses, lens care products, pharmaceuticals, ophthalmic medical devices, ophthalmic diagnostics, or vision care products or services.

\*Public service activities including work with Federal, State, and Local governments and their respective agencies, institutions of higher education, and non-profit educational or philanthropic entities should not be reported.

**🞎 NO**

**🞎 YES 🡪 If YES, complete the following:**

🞎 Stock shareholder or owner (in full or part)

Company Names:

🞎 Employee (receive a W2 from a designated entity)

Company Name:

🞎 Proprietary interest such as a patent or licensing agreement

Company Names:

🞎 Renumeration (e.g., consulting fees and other fees, gifts, honoraria, advisory board payment)

Company Names:

🞎 Educational grant or contract

Company Names:

🞎 Research grant or contract

Company Names:

🞎 Travel expenses, stipend or reimbursement

Company Names:

🞎 Non-COPE CE lecture or authorship honoraria

Company Names:

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Please Print Name Clearly Signature Date

***Please scan and email to editorial director Erinn Morgan at the following:*** [***erinn.morgan@pentavisionmedia.com.***](mailto:erinn.morgan@pentavisionmedia.com.)